Maetzel Andreas
Division of Clinical Decision Making, the Department of Health Policy, Management, and Evaluation, University Health Network, University of Toronto, Toronto, Ontario M5G 2C4, Canada.
J Rheumatol Suppl. 2005 Jan;72:51-3.
In the climate of rising healthcare expenditures the economic evaluation of new therapies becomes increasingly important in decision-making by health authorities. This article highlights some of the considerations regarding the economic assessment of drug treatments as they relate to rheumatic diseases, with emphasis on new biologic therapies such as tumor necrosis factor inhibitors.
在医疗保健支出不断增加的大环境下，新疗法的经济评估在卫生当局的决策中变得越来越重要。本文着重介绍了一些与风湿性疾病相关的药物治疗经济评估方面的考量因素，重点关注诸如肿瘤坏死因子抑制剂等新型生物疗法。
